Consonance Capital Partners’s Investment in Orsini Pharmacy

Consonance Capital Partners was advised by Latham & Watkins LLP and Bass, Berry & Sims PLC. Orsini Pharmaceutical Services was advised by Barone Law Group P.C., Levenfeld Pearlstein, LLC, and Brown & Fortunato, P.C.

Consonance Capital Partners, a leading healthcare-focused private equity fund, completed the recapitalization of Orsini Pharmaceutical Services, LLC, in partnership with the Company’s CEO and President, Michael Fieri.

Orsini is a leading rare disease specialty pharmacy differentiated by its personalized service and focus on complex conditions that require a high-touch patient journey.

Financial terms of the transaction were not disclosed.

Bass, Berry & Sims PLC advised Orsini with a team including Richard Eiler, Jeanne Marie Evans, Mallory Farrar, Mary Beth Fortugno (Picture), Maleaka N. Guice, Michael R. Hess, Elaine C. Naughton, Page Minton Smith, Jamie Gordon Steakley, Quyen Vo and Shannon Wiley.

Involved fees earner: Richard Eiler – Bass Berry & Sims; Jeanne Marie Evans – Bass Berry & Sims; Mallory Farrar – Bass Berry & Sims; Mary Beth Fortugno – Bass Berry & Sims; Jamie Gordon Steakley – Bass Berry & Sims; Maleaka Guice – Bass Berry & Sims; Michael Hess – Bass Berry & Sims; Page Minton Smith – Bass Berry & Sims; Elaine Naughton – Bass Berry & Sims; Quyen Vo – Bass Berry & Sims; Shannon Wiley – Bass Berry & Sims;

Law Firms: Bass Berry & Sims;

Clients: Orsini Pharmaceutical Services Inc;


Author: Ambrogio Visconti